Understanding how melanoma evolves resistance to targeted therapies
Melanoma Resistance Evolution Atlas (MREA) for identifying combinatorial targets to prevent and reverse MAPKi resistance
This study is looking at why some melanoma patients don’t respond well to certain treatments and aims to find better options for both those with the BRAFV600 mutation and those without, so that everyone can get more effective care based on their specific type of melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11045705 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind resistance to MAPK inhibitors in melanoma, particularly focusing on both BRAFV600 mutant and wildtype melanoma patients. By creating a comprehensive bank of patient-derived xenografts, the study aims to explore how different melanoma subtypes develop resistance to treatment. The approach includes analyzing the proteogenomic profiles of these subtypes to identify potential combinatorial therapies that could enhance treatment efficacy. Patients may benefit from insights that could lead to more effective treatment options tailored to their specific melanoma subtype.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with melanoma, particularly those with BRAFV600 mutant or wildtype subtypes.
Not a fit: Patients with melanoma who have already exhausted all treatment options or those with non-melanoma skin cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new combination therapies that effectively prevent or reverse resistance to melanoma treatments.
How similar studies have performed: Previous research has shown promise in understanding resistance mechanisms in melanoma, but this approach aims to provide a more comprehensive and novel perspective.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Lo, Roger S — University of California Los Angeles
- Study coordinator: Lo, Roger S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.